Producer
Biocon Biologics
Indian biotechnology and pharmaceutical company (NSE: BIOCON; Biocon Biologics listed separately; HQ Bangalore; ~₹150B revenue for Biocon group); Biocon is India's largest biopharmaceutical company and a major producer of complex small molecules and biologics including cyclosporine A API and immunosuppressants. Biocon Limited was founded in 1978 by Kiran Mazumdar-Shaw — one of India's most prominent female entrepreneurs — as an enzyme fermentation company, starting in a garage with ₹10,000 in capital. Today Biocon is a ~$3B revenue pharmaceutical company producing insulin biosimilars, cancer biologics, and complex small molecule APIs including cyclosporine A. The same Biocon that produces the cyclosporine A API for generic dry eye drops also produces trastuzumab biosimilar (Herceptin equivalent for breast cancer) and insulin analogs for diabetes — one Indian startup from 1978 spanning oncology, endocrinology, and ophthalmology API supply chains.
2
Inputs supplied
2
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Biocon Biologics supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Biocon Biologics makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Biosimilar Insulins (World #1 by Volume)
40%Oncology Biosimilars
30%Immunology Biosimilars
20%Small Molecule APIs + Industrial Enzymes
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Biocon is publicly known as a biosimilar insulin company, but the same Bengaluru fermentation facility that manufactures insulin biosimilars for 120+ countries also produces cyclosporine A API (~12% global market) — the primary immunosuppressant keeping transplanted kidneys, livers, and hearts from rejection. A single manufacturing disruption at Biocon's Bengaluru complex would simultaneously constrain insulin biosimilar supply for diabetic patients and cyclosporine A supply for organ transplant recipients — two completely separate patient populations with no clinical overlap. This dual exposure means Biocon represents a cross-therapeutic supply chain single point of failure connecting endocrinology, oncology, and transplant medicine. Their $3.335 billion 2022 acquisition of Viatris's biosimilars portfolio (including Pfizer's legacy pipeline) extends this concentration to cover biosimilar Humira (adalimumab for rheumatoid arthritis) and biosimilar Herceptin (trastuzumab for breast cancer) — making one Indian manufacturer from a Bengaluru garage the critical alternative supplier for at least six major drug supply chains globally.
Biocon Biologics ↗Origin2023
Kiran Mazumdar-Shaw founded Biocon in 1978 in a Bengaluru garage with 10,000 rupees to produce industrial enzymes — papain (from papaya) for beer clarification and meat tenderization, isinglass for brewing, and proteases for textile/food processing. She had trained as a brewmaster in Melbourne but could not get hired in India as a woman in the 1970s. The enzyme fermentation expertise became the platform for pivoting to pharmaceutical APIs (cyclosporine A, 1980s), then recombinant biologics (insulin, 1990s), then biosimilars (2000s). Biocon still operates the industrial enzymes division that started this entire pharmaceutical company. The same fermentation science that makes beer clear in a brewery also makes biosimilar insulin for diabetic patients — one technology, two completely different industries. Biocon is thus the closest Indian equivalent to the Ajinomoto pattern: a food ingredient company whose fermentation capabilities became essential pharmaceutical infrastructure.
Biocon Limited ↗